September 3, 2024 4:40pm

As I have written, share pricing satisfaction and disappointment will continue in alternating or leapfrogging sessions

Harvard Apparatus RT (OTCQB: HRGN +$0.65 down from +$0.72 with 2,199 shares traded – upping the hourly volume ante) “Humping” the volume to “jack” share pricing post newest $5 M financing or approximate 1.388 M additional shares after 4/15 private placement of 367,767 shares for a purchase price of $1.5 million and a unit price of $4.03 to “past or correct” outstanding of 14.53 M and float of 7.03 M shares?? Not rational, PONZI?

I say today what others won't, so you can do what others can't by sticking to the FACTS!

Never leave an investor uninformed!  

I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”

 

Tuesday: The Dow closed DOWN -626.15 points or -4.51%, the S&P closed DOWN -119.47 points or -2.12% while the Nasdaq closed DOWN -577.33 points or -3.26%

  • Monday was a holiday
  • Friday: The Dow closed UP +228.03 points or +0.55%, the S&P closed UP +56.44 points or +1.01% while the Nasdaq closed UP +197.19 points or +1.13%

 

Henry’omics: We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …

Indexes tumbled Tuesday as “tech” names struggled and new economic data rekindled fears around the health of the economy.

The market also took a leg down Tuesday morning after 2 readings of manufacturing production showed signs of weakness. S&P Global’s showed a decline from July to August, while the Institute for Supply Management’s came in under the level anticipated by economists. <CNBC>

  • This data reignited concerns around slowing growth within the U.S. economy, which helped drive a closely watched sell-off early last month.

 

Tuesday’s advance/decline line at the open was negative with 12 incliners, 21 decliners and 2 flats; ending with a negative at the close of 3 incliner, 29 decliners and 3 flats

  • Monday was a holiday
    Friday’s advance/decline line at the open was positive with 27 incliners, 5 decliners and 3 flats; ending with a luckily positive at the close of 18 incliner, 13 decliners and 4 flats

 

Metrics:

Tuesday, the IBB was down -1.69% and the XBI was down -2.57% while the VIX was up +5.11 points or up +32.86% at 20.66

  • Monday was a holiday
  • Friday, the IBB was down -0.11% and the XBI was up +0.35% while the VIX was down -0.71 point or down -4.53% at 14.95

 

All-time lows:

  • Editas Medicine (EDIT) at $3.49
  • Prime Medicine (PRME) at $3.86

 

RegMed Investors’ (RMi) pre-open: “September has many threats to expectation” … https://www.regmedinvestors.com/articles/13598

RegMed Investors (RMi) Research Note: Harvard Apparatus RT (OTCQB: HRGN) raises $5 M without name identification … https://www.regmedinvestors.com/articles/13590

 

Ebb and flow of MY covered sector cell and gene therapy session daily “endings”:

Q3/24

  • September – 1 negative close
  • August: 1 neutral, 10 positive and 11 negative closes
  • July: 1 market holiday. 1 day off, 6 negative, 1 neutral and 12 positive closes

 

Tuesday’s Closing Down (10 of 29):

  • Alnylam Pharmaceuticals (ALNY -$8.91 after Monday’s holiday and Friday’s -$23.32),
  • Blueprint Medicine (BPMC -$3.01 after Monday’s holiday and Friday’s +$1.93),
  • Vericel (VCEL -$2.61),
  • Beam Therapeutics (BEAM -$2.28 after Monday’s holiday and Friday’s -$0.16),
  • CRISPR Therapeutics (CRSP -$2.20 after Monday’s holiday and Friday’s +$0.17),
  • BioLife Solutions (BLFS -$1.45 after Monday’s holiday and Friday’s -$0.04)
  • Ultragenyx Pharmaceuticals (RARE -$1.07 after Monday’s holiday and Friday’s -$0.18),
  • Regenxbio (RGNX -$0.88 after Monday’s holiday and Friday’s +$0.22),
  • Intellia Therapeutics (NTLA -$0.82 after Monday's holiday and Friday’s -$0.56),
  • Lenz Therapeutics (LENZ -$0.67 after Monday’s holiday and Friday’s +$1.29),

Flat (3):

  • AxoGen (AXGN)
  • Bellicum Pharmaceuticals (BLCM)
  • Homology Medicine (FIXX)

Tuesday’s Closing Up (3 of 3):

  • Harvard Apparatus RT (OTCQB: HRGN +$0.65 after Monday’s holiday and Friday’s $0.00),
  • Mesoblast (MESO +$0.21 after Monday’s holiday and Friday’s +$0.27),
  • bluebird bio (BLUE +$0.0058 after Monday’s holiday and Friday’s -$0.03),

 

The BOTTOM LINE: The markets do not like uncertainty... small caps really hate uncertainty unless to its favor.

  • So many different interruptive factors in play that could contribute to sector slides and jives.

 

“Investors began September trading with a thud as stocks tumbled on Tuesday to start a historically tough month for markets, with AI darling Nvidia (NVDA) and chip names leading tech stocks down. The turn into the red comes amid a crucial week of data on the economy and labor market highlighted by an influential monthly jobs report.” <Yahoo Finance>

 

Reiterating, “There’s more room for “tactical downside in the weeks to come as we enter the gauntlet of weak months.”

  • As to the above … “There are a few theories for why September tends to be a weaker month for stocks. For one thing, investors returning from summer vacations tend to reassess portfolio positioning defensively. Companies prepare their budgets for the coming year and debate belt tightening. And mutual funds often engage in “window dressing” by selling positions at a loss to reduce the size of their capital-gains distributions.” < Bespoke Investment Group>

 

Q3 and September’s 1st week:

  • Tuesday ended with a negative close of 3 incliners, 29 decliners and 3 flats

 

The top three (3) performing in the session: 

  • Tuesday: Harvard Apparatus RT (OTCQB: HRGN), Mesoblast (MESO) and Lenz Therapeutics (LENZ)
  • Monday:
  • Friday: Blueprint Medicine (BPMC), Lenz Therapeutics (LENZ), and Verve Therapeutics (VERV)

The worst three (3) in the session: 

  • Tuesday: Alnylam Pharmaceuticals (ALNY), Blueprint Medicine (BPMC) and Vericel (VCEL)
  • Monday:
  • Friday: Ionis Pharmaceuticals (IONS) and Intellia Therapeutics (NTLA)

 

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.